216 related articles for article (PubMed ID: 35964087)
1. A prospective short-term study to evaluate methodologies for the assessment of disease extent, impact, and wound evolution in patients with dystrophic epidermolysis bullosa.
Paller AS; Pope E; Rudin D; Malyala A; Ramsdell D; Johnson R; Landy H; Murrell DF;
Orphanet J Rare Dis; 2022 Aug; 17(1):314. PubMed ID: 35964087
[TBL] [Abstract][Full Text] [Related]
2. Hindi translation and validation of quality of life score in Indian patients with epidermolysis bullosa; and its correlation with the clinical severity assessment scores: A cross-sectional study.
Bishnoi A; Manjunath S; Kishore K; De D; Handa S; Murrell DF; Mahajan R
Indian J Dermatol Venereol Leprol; 2022; 88(2):177-183. PubMed ID: 34491666
[TBL] [Abstract][Full Text] [Related]
3. A comparison study of outcome measures for epidermolysis bullosa: Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB).
Rogers CL; Gibson M; Kern JS; Martin LK; Robertson SJ; Daniel BS; Su JC; Murrell OGC; Feng G; Murrell DF
JAAD Int; 2021 Mar; 2():134-152. PubMed ID: 34409361
[TBL] [Abstract][Full Text] [Related]
4. Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI).
Loh CC; Kim J; Su JC; Daniel BS; Venugopal SS; Rhodes LM; Intong LR; Law MG; Murrell DF
J Am Acad Dermatol; 2014 Jan; 70(1):89-97.e1-13. PubMed ID: 24355263
[TBL] [Abstract][Full Text] [Related]
5. Psychometric Properties of the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa patient score (iscorEB-p): a patient-reported outcome measure.
Salamon G; Strobl S; Field-Werners U; Diem A; Schwieger-Briel A; Pope E
Br J Dermatol; 2024 Jun; 191(1):75-81. PubMed ID: 38261404
[TBL] [Abstract][Full Text] [Related]
6. Patient-reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: A global cross-sectional survey.
Eng VA; Solis DC; Gorell ES; Choi S; Nazaroff J; Li S; de Souza MP; Murrell DF; Marinkovich MP; Tang JY
J Am Acad Dermatol; 2021 Nov; 85(5):1161-1167. PubMed ID: 32199895
[TBL] [Abstract][Full Text] [Related]
7. Reliability and validity of the instrument for scoring clinical outcomes of research for epidermolysis bullosa (iscorEB).
Bruckner AL; Fairclough DL; Feinstein JA; Lara-Corrales I; Lucky AW; Tolar J; Pope E
Br J Dermatol; 2018 May; 178(5):1128-1134. PubMed ID: 29341069
[TBL] [Abstract][Full Text] [Related]
8. The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI): grading disease severity and assessing responsiveness to clinical change in epidermolysis bullosa.
Jain SV; Harris AG; Su JC; Orchard D; Warren LJ; McManus H; Murrell DF
J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):692-698. PubMed ID: 27580431
[TBL] [Abstract][Full Text] [Related]
9. Oleogel-S10 in Dystrophic Epidermolysis Bullosa: A Case Series Evaluating the Impact on Wound Burden Over Two Years.
Torres Pradilla M; Álvarez E; Novoa M; Lozano I; Trujillo M
Adv Ther; 2024 Feb; 41(2):867-877. PubMed ID: 38170434
[TBL] [Abstract][Full Text] [Related]
10. Itch in recessive dystrophic epidermolysis bullosa: findings of PEBLES, a prospective register study.
Mellerio JE; Pillay EI; Ledwaba-Chapman L; Bisquera A; Robertson SJ; Papanikolaou M; McGrath JA; Wang Y; Martinez AE; Jeffs E
Orphanet J Rare Dis; 2023 Aug; 18(1):235. PubMed ID: 37559055
[TBL] [Abstract][Full Text] [Related]
11. Impact of low-dose calcipotriol ointment on wound healing, pruritus and pain in patients with dystrophic epidermolysis bullosa: A randomized, double-blind, placebo-controlled trial.
Guttmann-Gruber C; Piñón Hofbauer J; Tockner B; Reichl V; Klausegger A; Hofbauer P; Wolkersdorfer M; Tham KC; Lim SS; Common JE; Diem A; Ude-Schoder K; Hitzl W; Lagler F; Reichelt J; Bauer JW; Lang R; Laimer M
Orphanet J Rare Dis; 2021 Nov; 16(1):473. PubMed ID: 34749770
[TBL] [Abstract][Full Text] [Related]
12. Our experience of using Losartan for esophageal stenosis in children with dystrophic form of congenital epidermolysis bullosa.
Oldakovskiy V; Murashkin N; Lokhmatov M; Gusev A; Tupylenko A; Budkina T; Yatzik S; Dyakonova E; Abaykhanov R; Fisenko A
J Pediatr Surg; 2023 Apr; 58(4):619-623. PubMed ID: 36566169
[TBL] [Abstract][Full Text] [Related]
13. A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa.
Tang JY; Marinkovich MP; Lucas E; Gorell E; Chiou A; Lu Y; Gillon J; Patel D; Rudin D
Orphanet J Rare Dis; 2021 Apr; 16(1):175. PubMed ID: 33849616
[TBL] [Abstract][Full Text] [Related]
14. Instrument for scoring clinical outcome of research for epidermolysis bullosa: a consensus-generated clinical research tool.
Schwieger-Briel A; Chakkittakandiyil A; Lara-Corrales I; Aujla N; Lane AT; Lucky AW; Bruckner AL; Pope E
Pediatr Dermatol; 2015; 32(1):41-52. PubMed ID: 24650374
[TBL] [Abstract][Full Text] [Related]
15. Validation and Repeatability of the Epidermolysis Bullosa Eye Disease Index in Dystrophic Epidermolysis Bullosa.
Chen VM; Kumar VSS; Noh E; Perloff J
Cornea; 2023 Jan; 42(1):74-79. PubMed ID: 36197337
[TBL] [Abstract][Full Text] [Related]
16. Burden of itch in epidermolysis bullosa.
Snauwaert JJ; Yuen WY; Jonkman MF; Moons P; Naulaers G; Morren MA
Br J Dermatol; 2014 Jul; 171(1):73-8. PubMed ID: 24506095
[TBL] [Abstract][Full Text] [Related]
17. Patient-reported outcomes and quality of life in dominant dystrophic epidermolysis bullosa: A global cross-sectional survey.
Fulchand S; Harris N; Li S; Barriga M; Gorell E; De Souza M; Murrell D; Marinkovich MP; Krishna Yenamandra V; Tang JY
Pediatr Dermatol; 2021 Sep; 38(5):1198-1201. PubMed ID: 34515355
[TBL] [Abstract][Full Text] [Related]
18. Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa.
Guide SV; Gonzalez ME; Bağcı IS; Agostini B; Chen H; Feeney G; Steimer M; Kapadia B; Sridhar K; Quesada Sanchez L; Gonzalez F; Van Ligten M; Parry TJ; Chitra S; Kammerman LA; Krishnan S; Marinkovich MP
N Engl J Med; 2022 Dec; 387(24):2211-2219. PubMed ID: 36516090
[TBL] [Abstract][Full Text] [Related]
19. A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplex.
So JY; Fulchand S; Wong CY; Li S; Nazaroff J; Gorell ES; de Souza MP; Murrell DF; Teng JM; Chiou AS; Tang JY
Orphanet J Rare Dis; 2022 Jul; 17(1):270. PubMed ID: 35841105
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics, healthcare use, and annual costs among patients with dystrophic epidermolysis bullosa.
Feinstein JA; Bruckner AL; Chastek B; Anderson A; Roman J
Orphanet J Rare Dis; 2022 Sep; 17(1):367. PubMed ID: 36175960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
